RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Accounts receivable, net

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndAccounts receivable, net (Million USD)YoY (%)
Dec 31, 20241,609+2.94%
Dec 31, 20231,563+8.40%
Dec 31, 20221,442+26.86%
Dec 31, 20211,137+28.40%
Dec 31, 2020885+39.75%
Dec 31, 2019634+54.63%
Dec 31, 2018410+45.62%
Dec 31, 2017281+39.91%
Dec 31, 2016201+13.20%
Dec 31, 2015178+133.85%
Dec 31, 201476-11.17%
Dec 31, 201386-40.30%
Dec 31, 2012143-21.78%
Dec 31, 2011183+1361.69%
Dec 31, 201013

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)